A new study presented at the 2024 Annual Meeting of The Menopause Society shows hormone therapy remains beneficial for women over 65, helping manage menopause symptoms like hot flashes and improving quality of life.

In this video from The Menopause Society Annual Meeting, Lauren Streicher, MD, talks about what to ask your patients about sexual function.

In a recent study presented at the 2024 Annual Meeting of The Menopause Society, insulin resistance was significantly reduced among postmenopausal women receiving hormone therapy vs placebo.

At the 2024 Menopause Society meeting, JoAnn Pinkerton, MD, highlighted phase 3 long-term safety data of elinzanetant from the OASIS 3 trial.

A discussion of vasomotor symptoms and the potential benefits of elinzanetant with Nanette Santoro, MD, from The Menopause Society annual meeting in Chicago, Illinois.

In a recent study presented at the 2024 Annual Meeting of The Menopause Society, 23% of patients with breast arterial calcifications on a mammogram had atherosclerotic cardiovascular disease, vs 13.9% without.

Wendie Berg. MD, PhD, explains new breast density reporting standards, cancer risks, and the importance of supplemental imaging for dense breast tissue.

A new study presented at the 2024 Annual Meeting of the Menopause Society found cognitive behavioral therapy can effectively address sexual concerns during menopause, improving overall well-being.

Nanette Santoro, MD, and Lauren Streicher, MD, MSCP, briefly highlight why they feel the annual Menopause Society is a great place for learning and collaboration.

In a recent study presented at the 2024 Annual Meeting of The Menopause Society, the prevalence of Alzheimer’s disease was significantly increased among women with prior trauma.

In a recent study presented at the 2024 Annual Meeting of The Menopause Society, women with certain adverse outcomes during pregnancy had an increased risk of cardiovascular disease later in life.

Amanda Williams, MD, MPH, FACOG, Interim Chief Medical Officer at March of Dimes, discusses the reported increase in the number of US counties with no obstetric care providers.

Female veterans with PTSD are twice as likely to experience early menopause and related health risks, according to a study presented at the 2024 Annual Meeting of The Menopause Society.

In a recent study presented at the 2024 Annual Meeting of The Menopause Society, 59% of nocturnal hot flashes occurred during the second half of the night, a time linked to increased cardiovascular disease risk.

A study presented at the 2024 Annual Meeting of The Menopause Society, found that women who reported physical intimate partner violence also demonstrated decreased working memory performance over time.

Data presented at the 2024 Annual Meeting of The Menopause Society highlighted greater reductions in hot flash severity among women receiving clinical hypnosis compared to those receiving cognitive behavioral therapy.

In a recent study, women with urinary incontinence were more likely to experience postpartum depression at both under and over 6 months after delivery.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

The advisory committee meeting will discuss the potential approval of oral sulopenem etzadroxil/probenecid tablets for treating urinary tract infections in women aged 18 years and older.

A recent study reveals that consuming fish during pregnancy is associated with a reduced risk of autism in children, while omega-3 supplements show no significant benefit.

In a recent study, neurodevelopmental outcomes did not significantly differ among children exposed to metformin in utero vs those unexposed.

In a recent study, women with higher levels of per- and polyfluoroalkyl substances during pregnancy reported increased weight and body fat later in life.

In this last episode, our panel discusses this patient population and the challenges around keeping them in the continuum of care.

The new single-handed inserter by CooperSurgical streamlines the placement of Paragard, a hormone-free IUD with over 30 years of proven efficacy, enhancing accessibility for both health care providers and patients.

In a recent study, rates of 12-month or longer contraceptive supply were increased by the implementation of a 12-month contraceptive supply policy.